A Sustained-Release Formulation of L-Dopa (Madopar HBS) in the Treatment of Nocturnal and Early-Morning Disabilities in Parkinson’s Disease
- 1 January 1987
- journal article
- madopar hbs
- Published by S. Karger AG in European Neurology
- Vol. 27 (1) , 126-134
- https://doi.org/10.1159/000116207
Abstract
In an open pilot study, 10 patients with Parkinson’s disease and nocturnal and/or early-morning disabilities were given Madopar HBS (hydrodynamically balanced system; mean dose 250 mg) shortly before retiring in addition to their usual daytime antiparkinsonian treatment. Eight patients derived worthwhile improvement; the most gratifying responses were seen in the relief of nocturnal bradykinesia, rigidity and tremor. Early-morning symptoms were also improved in 3 out of 5 patients, possibly as a secondary response to an improved nights sleep. Cramps, early-morning dystonia and pain, however, responded poorly. Overall results are sufficiently encouraging to warrant further controlled studies with Madopar HBS in what has been a relatively neglected area of distress for many patients with Parkinson’s disease.Keywords
This publication has 0 references indexed in Scilit: